Promising combo targets tough leukemia in vulnerable patients
NCT ID NCT07451912
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a combination of three drugs—venetoclax, a hypomethylating agent (azacitidine or decitabine), and low-dose cytarabine—can effectively treat adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CEBPA-mutated AML) who are not healthy enough for intensive chemotherapy. The 29 participants will receive two cycles of induction therapy, and those who respond well will continue with at least four more cycles. Researchers will track how long patients stay cancer-free, their remission rates, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax, azacitidine or decitabine, and low-dose cytarabine
What this could lead to
If successful, this combination could offer a more effective and tolerable treatment option for people with this specific type of AML who cannot handle standard intensive chemotherapy.
What could go wrong
This is an early-phase trial with only 29 participants, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it will improve long-term survival or prevent relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••